Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01085214 · OUTCOME

Overall Response Rate

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma · Source last updated 2015-08-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Up to 2 years

What was measured

Overall Response: Stringent Complete Response (sCR) + Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR).

Analysis population: All participants who received study treatment

Groups in this outcome

AZD6244 (Selumetinib) Treatment

Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD6244 (Selumetinib) Treatment36

Reported measurements

Response: Total
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment2Not reportedNot reportedNot reportedNot reported
Response: sCR
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment0Not reportedNot reportedNot reportedNot reported
Response: CR
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment0Not reportedNot reportedNot reportedNot reported
Response: VGPR
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment1Not reportedNot reportedNot reportedNot reported
Response: PR
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment1Not reportedNot reportedNot reportedNot reported
Other Status: Stable Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment17Not reportedNot reportedNot reportedNot reported
Other Status: Progressive Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment13Not reportedNot reportedNot reportedNot reported
Could not be assessed
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
AZD6244 (Selumetinib) Treatment4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Response: Total
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Response: sCR
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Response: CR
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Response: VGPR
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Response: PR
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    Other Status: Stable Disease
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        13
    title
    Other Status: Progressive Disease
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Could not be assessed
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Overall Response: Stringent Complete Response (sCR) + Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR).
groups
  1. description
    Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    AZD6244 (Selumetinib) Treatment
param Type
NUMBER
population Description
All participants who received study treatment
reporting Status
POSTED
time Frame
Up to 2 years
title
Overall Response Rate
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice